Company intelligence / Profile preview
Abdera Therapeutics
South San Francisco, California, United Statesabderatx.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 1
01
Overview
Abdera Therapeutics has initiated a Phase 1 clinical trial for its lead program ABD‑147, a DLL3-targeting radiopharmaceutical using Actinium‑225 to treat SCLC and LCNEC. The company also has preclinical data on its second program, ABD‑320 targeting the antigen 5T4. No efficacy or safety results from human trials have been published yet as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Radiopharmaceuticals (radiotherapeutics)Antibody-based biologics
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Abdera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abdera Therapeutics.